Prevalence of subnormal adrenal responses to low dose synthetic ACTH (synacthen) in children receiving ≥ 500 mcg daily of the inhaled steroid fluticasone propionate (FP) Source: Eur Respir J 2003; 22: Suppl. 45, 310s Year: 2003
Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma Source: Eur Respir J 2003; 21: 633-636 Year: 2003
The effect of inhaled budesonide on adrenal and growth suppression in asthmatic children Source: Eur Respir J 2006; 27: 316-320 Year: 2006
Adrenal function with low acth doses in asthmatic children with inhaled corticosteroids Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids Source: Eur Respir J 2008; 32: 1047-1052 Year: 2008
High doses of inhaled fluticasone propionate dose-dependently suppress adrenal cortical function in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma Source: Eur Respir J 2009; 33: 1277-1286 Year: 2009
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Is the combination of long-acting β2 -agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Effects of esomeprazole 40 mg twice-daily in adults with moderate to severe asthma who had been treated previously with inhaled steroids and long-acting β2 -agonists Source: Eur Respir J 2005; 26: Suppl. 49, 278s Year: 2005
Low risk of adrenal dysfunction in children with severe asthma treated with high-dose inhaled glucocorticoids Source: Eur Respir J 2005; 26: Suppl. 49, 161s Year: 2005
Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010